CN115052891A - 癌症治疗中il-15和cd40激动剂的组合免疫疗法 - Google Patents

癌症治疗中il-15和cd40激动剂的组合免疫疗法 Download PDF

Info

Publication number
CN115052891A
CN115052891A CN202080092819.9A CN202080092819A CN115052891A CN 115052891 A CN115052891 A CN 115052891A CN 202080092819 A CN202080092819 A CN 202080092819A CN 115052891 A CN115052891 A CN 115052891A
Authority
CN
China
Prior art keywords
combination
body weight
agonist
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092819.9A
Other languages
English (en)
Chinese (zh)
Inventor
E·斯密特斯
J·范奥德奈尔德
M·彼特尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antwerp University Hospital
Universiteit Antwerpen
Original Assignee
Antwerp University Hospital
Universiteit Antwerpen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antwerp University Hospital, Universiteit Antwerpen filed Critical Antwerp University Hospital
Publication of CN115052891A publication Critical patent/CN115052891A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080092819.9A 2019-12-06 2020-12-04 癌症治疗中il-15和cd40激动剂的组合免疫疗法 Pending CN115052891A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214049.9 2019-12-06
EP19214049 2019-12-06
PCT/EP2020/084665 WO2021110930A1 (en) 2019-12-06 2020-12-04 Combination immunotherapy of il-15 and cd40 agonist in cancer treatment

Publications (1)

Publication Number Publication Date
CN115052891A true CN115052891A (zh) 2022-09-13

Family

ID=68808124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092819.9A Pending CN115052891A (zh) 2019-12-06 2020-12-04 癌症治疗中il-15和cd40激动剂的组合免疫疗法

Country Status (8)

Country Link
US (1) US20220411524A1 (https=)
EP (1) EP4069739A1 (https=)
JP (1) JP2023505303A (https=)
CN (1) CN115052891A (https=)
AU (1) AU2020395907A1 (https=)
CA (1) CA3163777A1 (https=)
IL (1) IL293613A (https=)
WO (1) WO2021110930A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024523181A (ja) * 2021-06-03 2024-06-28 アペクシジェン アメリカ， インコーポレイテッド Ｃｄ－４０アゴニストを用いてがんを処置する方法
EP4415757A4 (en) * 2021-10-15 2025-10-08 Univ Rockefeller COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068299A1 (en) * 2001-08-23 2003-04-10 Murphy William J. Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068299A1 (en) * 2001-08-23 2003-04-10 Murphy William J. Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN AUDENAERDE: "ANTI-TUMOURAL EFFECTS OF IL-15 AND CD40 STIMULATION AS A NOVEL COMBINATION IMMUNOTHERAPY FOR PANCREATIC CANCER", 29 June 2018 (2018-06-29), pages 393 *

Also Published As

Publication number Publication date
IL293613A (en) 2022-08-01
US20220411524A1 (en) 2022-12-29
JP2023505303A (ja) 2023-02-08
WO2021110930A1 (en) 2021-06-10
EP4069739A1 (en) 2022-10-12
CA3163777A1 (en) 2021-06-10
AU2020395907A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
US12043664B2 (en) Methods for treating vascular leak syndrome and cancer
US20200368321A1 (en) Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody
JP2022058698A (ja) 抗ｐｄ－１抗体と他の抗癌剤の組合せを使用する腎癌の処置
JP7200093B2 (ja) がん治療用ｔｌｒ９アゴニストを用いた免疫調節
JP6805428B2 (ja) Ｃｅａｃａｍ１に対するヒト化抗体
AU2009270434B2 (en) Composition comprising in vitro expanded T-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer
JP2018524347A (ja) 血液がん及び固形腫瘍の治療のための併用療法
TW201722985A (zh) Cd80胞外域多肽及其用於癌症治療
KR20210013777A (ko) 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
US20240033257A1 (en) Use of ppar-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug
JP2021502423A (ja) 免疫系の複数のアームを修飾することによってがんを治療するための方法及び組成物
JP2025527534A (ja) 抗－ヒト表皮成長因子受容体２（ｈｅｒ２）キメラ抗原受容体（ｃａｒ）を含むナチュラルキラー細胞を投与する方法
CN115052891A (zh) 癌症治疗中il-15和cd40激动剂的组合免疫疗法
CA3081748A1 (en) Methods of treating a tumor
Hung et al. GD2-Targeted immunotherapy of neuroblastoma
JP2023551733A (ja) 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの併用免疫療法
McCormick Immunotherapeutics targeting solid tumor vasculature: Dendritic cell vaccines and antibody-MHC fusion proteins
US20240010740A1 (en) Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
HK40056474A (en) Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody
JP2025538867A (ja) フコシル化細胞及び免疫チェックポイント阻害剤を含有する併用療法のための組成物及びシステム、並びにその製造及び使用
WO2024002074A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK1161895A (en) Composition comprising in vitro expanded t-lymphocytes and vessel formation inhibitors suitable in the treatment of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220913